



Innovative Bioanalysis, Inc.
3188 Airway Ave Suite D
Costa Mesa, CA 92626
www.InnovativeBioanalysis.com
Email: Albert.Brockman@innovativebioanalysis.com

SARS-CoV-2 USA-CA1/2020

CLIENT: JIBE LIGHTING B.V.
PROJECT: JIBE ION-MINI SURFACE TESTING
PRODUCT: Ablatum ION-Mini
CAP LIC NO: 886029801
CLIA LIC NO: 05D0955926
STATE ID: CLF 00324630

CHALLENGE VIRUS: SARS-CoV-2 USA-CA1/2020



ABSTRACT: EFFICACY OF THE JIBE LIGHTING ABLATUM ION-MINI DEVICE AGAINST SARS-CoV-2


Background: This in vitro study was designed to determine the efficacy of the Ablatum-ION-Mini unit. The product is a commercially available mobile disinfection device manufactured by Jibe Lighting Netherlands. The Ablatum-ION-Mini unit is designed to be placed throughout a commercial or retail space and decrease the concentration of pathogens in the air and on surfaces when it is operating, to sanitize enclosed spaces and their contents. For this challenge, the SARS-CoV-2 USA-CA1/2020 pathogen was used. Coronavirus can be spread through the air and by touching contaminated surfaces. There is a demand for disinfectant devices that have a proven ability to reduce infectious pathogens in the air thereby reducing the risk of human infection and transmission. Jibe Lighting supplied a pre-packaged Ablatum-ION-Mini™ wall mountable unit for testing purposes. For the testing, power was supplied through a power regulated 120v outlet with surge protector and backup battery system. Test procedures were followed using internal SOPs for aerosolized viral pathogen challenges and subsequent decontamination. All internal SOPs and processes follow GCLP guidelines and recommendations.

EQUIPMENT PROVIDED:

MANUFACTURER: JIBE LIGHTING B.V.

MODEL: Ablatum-ION-Mini

SERIAL #: N/A






ABLATUM ION-MINI EQUIPMENT:


The equipment arrived at the laboratory pre-packaged from the manufacturer and was inspected for damage upon arrival. The device was powered on to check for normal operations and confirm it could create positively and negatively charged ions.

VIRAL CHALLENGE TESTING CHAMBER:

A metal and glass bio safety chamber, 72" W x 30" H x 30" D with sealed seams was used for a surface testing site. The air temperature fluctuated slightly through the test and ranged from 70°F to 71°F. During the control testing and the viral load tests the temperature fluctuation was consistent. The ambient humidity inside the test chamber was 39%. All seals for the chamber were confirmed and all equipment used had a function tests to confirm working conditions. For calibrated equipment, calibration records were checked to confirm operational status.

TESTING CHAMBER





EXPERIMENTAL SUMMARY:

- Prior to the initial control test and following each trial run the testing area was decontaminated and prepped per internal procedures.
- Temperature during all test runs was approximately 70F +/- 2F with a relative humidity of 39%.
- Directly next to samples there were two AIC2 Air Ion Counter continually logging the negative and positive ion counts.
- The Ablatum ION-Mini was placed on the side of the testing chamber opposite the glass slides for surface sampling.
- Ion concentration averages at the sample site was approx. 82k per cm³.
- Surface samples consisted of a 3" x 1.5" piece of sterile glass, 0.125" thick.
- Samples were taken at T-0, T-15, and T-30 minutes.
- For sample collection swabs were moistened with the viral suspension liquid and rubbed across the testing surfaces to pull as much standing viral media as possible.
- Swabs were sealed in individual tubular containers and stored in a sealed box for the duration of the test so no further ions could interact with them.
- Controls and viral challenge surface inoculation and sample collection were done in the same manner.
- During control testing average ion concentrations were -500 cm³.
- During control testing there was no airflow within the biosafety hood.

VIRUS STRAIN BACKGROUND:


The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through the BEI Resources, BIAID, NIH SARS-Related Coronavirus 2, Isolate USA-CA1/2020, NR-52382.

POST DECONTAMINATION:


At the conclusion of each viral challenge test the UV system inside the testing chamber was activated for 30 minutes. All test equipment was cleaned at the end of each test with a 70% alcohol solution.




ION CONCENTRATION LEVELS AVERAGE -82K CM3



ION CONCENTRATION LEVELS AVERAGE +32K CM3





TCID50 PROCEDURE:

Materials and Equipment:

- Certified Biological Safety Cabinet
- Micropipette and sterile disposable aerosol resistant tips – 20uL, 200uL, 1000uL.
- Inverted Microscope
- Tubes for dilution
- Hemocytometer with cover slip
- Cell Media for infection
- Growth Media appropriate for cell line
- 0.4 % Trypan Blue Solution
- Lint Free Wipes saturated with 70% isopropyl alcohol
- CO₂ Incubator set at 37°C or 34°C or other temperature indicated.

Procedure:

1. One day prior to infection, prepare 96 well dishes by seeding each well with Vero E6 cells in DMEM plus 7.5 % fetal bovine serum, 4mM Glutamine, and antibiotics.
2. On the day of infection, make dilutions of virus sample in PBS.
3. Make a series of dilutions at 1:10 of the original virus sample. First tube with 2.0 mL PBS and subsequent tubes with 1.8mL
4. Vortex Viral samples, transfer 20 uL of virus to first tube, vortex, discard tip.
5. With new tip, serial dilute subsequent tips transferring 200 uL.

Additions of virus dilutions to cells

1. Label lid of 96 well dish by drawing grid lines to delineate quadruplicates and number each grid to correspond to the virus sample and label the rows of the plate for the dilution which will be plated.
2. Include 4 Negative wells on each plate which will not be infected.
3. Remove all but 0.1 mL of media from each well by vacuum aspiration.
4. Starting from the most dilute sample, add 0.1 mL of virus dilution to each of the quadruplicate wells for that dilution
5. Infect 4 wells per dilution, working backward.
6. Allow the virus to absorb to cells at 37°C for 2 hours.
7. After absorption, remove virus inoculum. Start with the most dilute and work backwards
8. Add 0.5 mL infection medium to each well being careful to not touch the wells with the pipette.
9. Place plates at 37°C and monitor CPE using the inverted microscope over a period of 1 to 4 weeks.



10. Record the number of positive and negative wells.

CONTROL:

One Control test was conducted without the Ablatum-ION-Mini unit in the testing chamber. Control samples were taken at each of the corresponding sample times used for the viral challenge trial. Control testing was used for the comparative baseline to assess the viral reduction when the Ablatum-ION-Mini device was operated in the challenge trial, to enable net reduction calculations to be made. An RKI O3 sensor was outfitted to the room and calibrated down to 1PPB accuracy to monitor O3 level during testing. During the control temperature and relative humidity were monitored. Prior to running the viral challenges temperature and humidity were confirmed to be in relative range to the control +/- 3%.

VIRAL STOCK: SARS-CoV-2 USA-CA1/2020 (BEI NR-52382)

TEST	SPECIFICATIONS	RESULTS
Identification by Infectivity in Vero 6 cells	Cell Rounding and Detachment	Cell Rounding and Detachment
Next Generation Sequencing (NGS) of complete genome using Illumina® iSeq™ 100 Platform (Approx. 940 Nucleotides)	≥ 98% identity with SARS-CoV 2, isolate USA-CA1/2020 GenBank: MN994467.1 ≥ 98% identity with SARS-CoV 2, strain FDAARGOS_983 isolate USA-CA1/2020 GenBank: MT246667.1	99.9% identity with SARS-CoV 2, isolate USA-CA1/2020 GenBank: MN994467.1 100% identity with SARS-CoV 2, strain FDAARGOS_983 isolate USA-CA1/2020 GenBank: MT246667.1
Titer by TCID50 in Vero E6 Cells by Cytopathic effect	Report Results	2.8 X 10 ⁵ TCID50 per mL in 5 days at 37°C and 5% CO2
Sterility (21-Day Incubation) Harpos HTYE Broth, aerobic Trypticase Soy Broth, aerobic Sabourad Broth, aerobic Sheep Blood Agar, aerobic Sheep Blood Agar, anaerobic Thioglycollate Broth, anaerobic DMEM with 10% FBS	No Growth No Growth No Growth No Growth No Growth No Growth No Growth	No Growth No Growth No Growth No Growth No Growth No Growth No Growth




Sterility (21-Day Incubation)		
Harpos HTYE Broth, aerobic	No Growth	No Growth
Trypticase Soy Broth, aerobic	No Growth	No Growth
Sabourad Broth, aerobic	No Growth	No Growth
Sheep Blood Agar, aerobic	No Growth	No Growth
Sheep Blood Agar, anaerobic	No Growth	No Growth
Thioglycollate Broth, anaerobic	No Growth	No Growth
DMEM with 10% FBS	No Growth	No Growth
Mycoplasma Contamination		
Agar and Broth Culture	None Detected	None Detected
DNA Detection by PCR of extracted	None Detected	None Detected
Test Article nucleic acid.		

Inoculation of Surface Samples

Surface inoculation consisted of applying exactly 1 ml of viral media to each coupon with a calibrated Eppendorf pipette utilizing filtered pipette tips. Coupons were standard sterile 25mm x 75mm slides. Once applied, the media was spread thin using a disposable spatula and allowed to dry for 10 minutes. The starting concentration of virus that was applied was 4.53×10^6 TCID₅₀/mL. After several tests for recovery, it was determined that the most efficient method of recovering viable virus would be a 2 mL rinse in viral media followed by a swab of the inoculated area.

Test Results: Surface Inoculation

Performed in the same manner as the control testing, the following deactivation rates were observed for direct surface inoculation in the challenge trial. Collection at each time point was done by swab and rinse of the coupon. Samples were collected by a technician at specified time from the bio safety container. The graph below represents the data for the experiment and the control, as it pertains to surface inoculation.



Conclusion:

In conclusion, the Ablatum ION-Mini™ demonstrated a considerable reduction in the concentration of SARS-CoV-2 on surfaces at roughly 79 percent at 15 minutes and 99.99% at 30 minutes. Its important to note that the lower limit of the titration is 120 TCID50/mL. This is represented by the 120 in the data table above. It is understood that there are several products manufactured by JIBE lighting that are designed to produce the same effect. For the purposes of this experiment, these results pertain to the Ablatum-ION-Mini™ supplied by JIBE lighting. Identical instruments theoretically may or may not perform the same as we can only speak to the product tested.

DISCLAIMER:

The Innovative Bioanalysis, Inc. ("Innovative Bioanalysis") laboratory is not certified or licensed by the United States Environmental Protection Agency and makes no equipment emissions claims pertaining to ozone or byproduct of any Jibe Lighting Ablatum-ION-Mini device. Innovative Bioanalysis makes no claims to the overall efficacy of any Ablatum ION-Mini. The experiment results are solely applicable to the device used in the trial. The results are only representative of the experiment design described in this report. Innovative Bioanalysis makes no claims as to the reproducibility of the experiment results given the possible variation of experiment results even with an identical test environment, viral strain, collection method, inoculation, viral media, cell type, and culture procedure. Innovative Bioanalysis makes no claims to third parties and takes no responsibility for any consequences arising out of the use of, or reliance on, the experiment results by third parties.



DocuSigned by:
Dana Yee
7D5A69A0907947B...

3/12/2021

Dr. Dana Yee M.D
Clinical Pathologist and Medical Director

Date

DocuSigned by:
Sam Kabbani
8B4B282DF4B34A3...

3/11/2021

Sam Kabbani, MS, BS, MT(ASCP), CLS
Chief Scientific Officer, Innovative Bioanalysis

Date

DocuSigned by:
Albert Brockman
06DF5677A0B2400...

3/11/2021

Albert Brockman
Chief Biosafety Officer, Innovative Bioanalysis

Date

DocuSigned by:
Kevin Noble
5DF2797BAA78421

3/11/2021

Kevin Noble
Chief Operating Officer, Innovative Bioanalysis

Date